1031eTiP Phase I expansion study of the first-in-class non-cellular targeting antibody-drug conjugate (ADC), micvotabart pelidotin (MICVO), in patients with select advanced solid tumors
Year: 2025
Type: article
Source: Annals of Oncology
Authors: D. Roda Perez, G.M. Cote, A. Williams, D.E. Castellano Gauna, K. Clifton, B.A. Carneiro, J.S. Wang, A.I. Spira, J. Henry, F. Tsai, V. Moreno Garcia, S. Rottey, E. Felip, A. Elfiky, O. Bogg, V. Attaya, M. Crochiere, S. He, H. Wang, J-P. Machiels
Institutions: Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, Massachusetts General Hospital, Sarah Cannon Research Institute, Hospital Universitario 12 De Octubre, Washington University in St. Louis, Brown University, Virginia Cancer Specialists, HealthONE, HonorHealth, Hospital Universitario Fundación Jiménez Díaz, Ghent University Hospital, Vall d'Hebron Hospital Universitari, Cliniques Universitaires Saint-Luc, UCLouvain
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415940694
FWCI:
Cites:
Cited by:
Related to: